



August 2009

FDA CONCLUDES INSPECTIONS AT TWO ETHYPHARM'S FACILITIES

Paris, France... Ethypharm, a pharmaceutical technology based company, announced that United States Food and Drug Administration (FDA) recently completed two Inspections at its manufacturing facilities, located in Grand Quevilly and Chateaufort en Thymerais, near Paris, France, for the general review of cGMP's compliance and the further launch of three products on the American market.

Further to Ethypharm's responses to the FDA 483 forms, the FDA concluded to maintain the agreement on the existing US products.

Both sites of Grand Quevilly and Chateaufort en Thymerais were also successful for the PAI's (Pre Approval Inspections) of the related three ANDA's (Abbreviated New Drug Applications).

« It's a great satisfaction for Ethypharm on a worldwide point of view and for our plants in particular. This further demonstrates our commitment to quality in every aspect of our development and industrial programs. It confirms our commitment to high quality standards in a more and more stringent and demanding regulatory environment », declared Michel Couquelet, Senior VP Corporate Quality at Ethypharm.

About ETHYPHARM
www.ethypharm.com

Ethypharm is a pharmaceutical laboratory specialized in controlled release systems of medicinal products by the oral route. Its principal therapeutic fields concern pain relief, cardio-vascular and the central nervous system.

The Company has more than 50 products launched by marketing partners of international repute in over 70 countries. Ethypharm develops and manufactures its products in compliance with the current world-wide pharmaceutical Norms. The Company has developed a wide range of technological platforms for the administration of medicinal products by the oral route, including extended release, taste-masked orodispersible forms and ameliorated solubility systems for active substances with low solubility.

Ethypharm is present on the principal world health markets with its manufacturing plants and Research & Development centres in Europe, in the United States of America and in Asia. The Laboratory employs a world-wide work force of 850.

For further information please contact:
Caroline Guinet, Corporate Communications
Tel: +33 (0)1 41 12 17 20
guinet.caroline@ethypharm.com

Ethypharm
194 Bureaux de la Colline
92 213 Saint-Cloud, France
Tel: +33 1 41 12 17 20

www.ethypharm.com

